Retatrutide's TRIUMPH Trials, Explained: A Trial-by-Trial Guide to the Phase 3 Evidence

Retatrutide produced the largest weight-loss numbers obesity medicine has ever recorded — but those numbers come from a sprawling Phase 3 program called TRIUMPH, and not every trial in it has reported. This guide walks through each TRIUMPH trial one at a time: what it tests, how big it is, where it stands, and what the finished ones actually found. Retatrutide (LY3437943) is an investigational once-weekly subcutaneous triple agonist that activates the GLP-1, GIP, and glucagon receptors simultaneously, developed by Eli Lilly, and is the first triple agonist of its kind to reach Phase 3 testing.

Understanding the trials matters because "how much weight does retatrutide cause" has more than one answer depending on which population was studied — and because the gap between a monitored clinical trial and an unregulated vial bought online is the single most important thing a prospective user can understand. For the biology behind the numbers, see how retatrutide works as a triple agonist; for where it sits among other weight-loss and metabolic peptides, the comparisons below put it in context.

What is retatrutide's TRIUMPH program?

TRIUMPH is the umbrella name for Eli Lilly's global Phase 3 clinical-trial program testing retatrutide, an investigational triple GLP-1/GIP/glucagon receptor agonist administered once weekly by subcutaneous injection. Begun in 2023, the program enrolled more than 5,800 participants across its core registrational trials, plus a separate cardiovascular-outcomes study of roughly 10,000 patients. Each trial targets a different population — general obesity, obesity with type 2 diabetes, obesity with established cardiovascular disease — and together they form the evidence base behind retatrutide's expected regulatory submission.

The program's design was formalized in a published rationale paper (Giblin et al., Diabetes, Obesity and Metabolism, 2026;28(1):83-93), which laid out the registrational trials and their nested substudies for conditions such as knee osteoarthritis and obstructive sleep apnea. The structure reflects how modern obesity drugs are now developed: not as a single weight-loss study, but as a portfolio that tests one compound across the cluster of conditions that travel with obesity. Retatrutide is the first triple agonist to be carried through a program of this scale, which is why each readout has drawn outsized attention.

How did retatrutide reach Phase 3? The Phase 2 foundation

Retatrutide earned its Phase 3 program on the strength of one headline number: in its peer-reviewed Phase 2 obesity trial, participants on the 12 mg dose lost an average of 24.2% of body weight over 48 weeks, compared with 2.1% on placebo (Jastreboff et al., New England Journal of Medicine, 2023; n=338). That result — larger than anything semaglutide or tirzepatide had shown at comparable points — is what justified the multi-trial program that followed. The Phase 2 weight loss was dose-dependent: −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg, and −24.2% at 12 mg.

Two companion Phase 2 trials rounded out the early evidence. In adults with type 2 diabetes, the 12 mg dose produced roughly 16.9% mean weight loss at 24 weeks alongside glycemic improvement, with dulaglutide 1.5 mg as an active comparator (Rosenstock et al., The Lancet, 2023; n=281). A liver-focused substudy in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) found that liver fat fell by 82.4% at 24 weeks on the 12 mg dose, and normal liver-fat content (under 5%) was restored in 86% of participants versus 0% on placebo (Harrison et al., Nature Medicine, 2024; n=98). Critically, all three of these trials are peer-reviewed and published — a status that matters when comparing them to the Phase 3 results below.

The TRIUMPH trials, one by one — what each tests and where it stands

The TRIUMPH program is built from several large trials that each test retatrutide in a different population, which is why a single "retatrutide weight loss" figure is misleading. As of June 2026, two of the core trials have reported topline results (TRIUMPH-1 and TRIUMPH-4), while the type 2 diabetes trial, the cardiovascular-disease trial, and the large cardiovascular-outcomes study are still running. The roster below maps each trial — its population, size, duration, and current status — and the sections that follow explain what the finished ones found.

TRIUMPH-1 is the pivotal obesity trial and the program's anchor: a randomized, placebo-controlled study of 2,339 adults with obesity or overweight but without diabetes, dosed over 80 weeks, with substudies for knee osteoarthritis and obstructive sleep apnea nested inside it. TRIUMPH-2 extends the same basket design to people who also have type 2 diabetes, and TRIUMPH-3 to people with established cardiovascular disease — both still enrolling or in follow-up. TRIUMPH-4 tested retatrutide specifically in adults with obesity and knee osteoarthritis over 68 weeks. TRIUMPH-OUTCOMES is the largest and longest piece — a cardiovascular-outcomes trial of around 10,000 patients designed to show whether the drug reduces hard events such as heart attack, stroke, and cardiovascular death, not just weight. A companion Phase 3 diabetes trial, TRANSCEND-T2D-1, has already been published in The Lancet (2026).

What have the completed trials shown? TRIUMPH-1 and TRIUMPH-4

Two TRIUMPH trials have reported as of June 2026, and both were strongly positive — but both arrived as company "topline" announcements rather than peer-reviewed publications, a distinction worth holding onto. TRIUMPH-4 reported a mean weight reduction of 28.7% at 68 weeks on the highest dose, alongside clinically meaningful knee-osteoarthritis pain relief, and met all primary and key secondary endpoints (Eli Lilly topline, December 2025). TRIUMPH-1, the pivotal obesity trial, reported weight loss of approximately 28% at the top dose over 80 weeks, with a reported 104-week extension reaching near 30% (Eli Lilly topline, May 2026). Full datasets are still pending journal publication.

The topline-versus-peer-reviewed distinction is not pedantry. A topline announcement is a company's summary of its own primary endpoints, released to investors and the press; the complete data — secondary endpoints, full safety tables, subgroup analyses, and independent peer review — come months later when the trial is published in a journal. Headline percentages occasionally shift between a topline release and the final paper as the full population is analyzed. Most peptide content treats Lilly's press-release numbers as settled fact; the more accurate reading is that TRIUMPH-1 and TRIUMPH-4 are very promising topline results awaiting peer-reviewed confirmation, while the Phase 2 trials above are already through that gate.

There is also a placebo-adjustment nuance readers should know. TRIUMPH-4's ~28.7% total weight loss corresponds to roughly 26.6% after subtracting the placebo group's change — the placebo-adjusted figure is the one that isolates the drug's specific effect. Both numbers are legitimate; they answer slightly different questions ("how much did people on the drug lose" versus "how much of that is attributable to the drug").

How does retatrutide compare to tirzepatide and semaglutide?

On the numbers alone, retatrutide looks like the most powerful weight-loss agent yet — roughly 28% mean weight loss in TRIUMPH-1 versus about 22.5% for tirzepatide in SURMOUNT-1 and about 14.9% for semaglutide in STEP 1. But those figures come from three separate trials with different patients, doses, and durations, so the comparison is suggestive rather than a verdict. As of June 2026, no head-to-head trial pitting retatrutide directly against tirzepatide or semaglutide has reported, which means the ranking below reflects cross-trial inference, not a controlled comparison. For a deeper breakdown, see retatrutide versus tirzepatide and semaglutide.

The mechanistic reason retatrutide may go further is its third receptor. Tirzepatide is a dual GLP-1/GIP agonist, and semaglutide is a single GLP-1 agonist; retatrutide adds glucagon-receptor activation, which increases energy expenditure and drives the pronounced liver-fat reductions seen in Phase 2. That added pathway appears to come with a trade-off in tolerability — more frequent gastrointestinal events at higher doses — which is why the cross-trial weight-loss edge should be weighed against the side-effect profile rather than read in isolation. Until a controlled active-comparator trial reports, "retatrutide is stronger than tirzepatide" remains a reasonable hypothesis, not an established fact.

What safety signals have the trials raised?

Retatrutide's most common side effects are gastrointestinal — nausea, vomiting, and diarrhea — and they are dose-dependent, mostly mild to moderate, and concentrated during dose escalation, exactly as expected for this drug class. In the Phase 2 obesity trial, nausea occurred in 47% and vomiting in 21% of participants at the 12 mg dose, declining at lower doses and tending to ease with continued treatment. The trials also surfaced something new: dysesthesia, an abnormal and sometimes unpleasant skin sensation, appeared in the Phase 3 trials at the higher doses but had not been characterized in Phase 2.

The dysesthesia signal is the most notable Phase 3-specific finding, and its rate varies by population and dose. In TRIUMPH-4, dysesthesia was reported in about 20.9% of participants at 12 mg and 8.8% at 9 mg, versus 0.7% on placebo; in the pivotal obesity trial it ran around 12.5% at the top dose; and in the companion diabetes trial TRANSCEND-T2D-1 it was lower, around 4.4%. The sensation is generally mild and not the same as the peripheral neuropathy seen in poorly controlled diabetes, but it is a genuinely novel signal that emerged only at Phase 3 scale and is being actively monitored. A fuller breakdown of these adverse events by dose and route is covered in retatrutide's side effects.

What does the trial data mean if you're considering gray-market retatrutide?

Here is the disconnect that matters most: every weight-loss number in the TRIUMPH program was produced with pharmaceutical-grade retatrutide, dosed precisely under medical supervision — and that is not what is being sold online. Retatrutide is investigational and approved nowhere, so every consumer vial comes from the unregulated research-chemical market, where what is on the label and what is in the vial are two separate questions. The trial efficacy is real; whether it transfers to an unverified vial depends entirely on what that vial actually contains and at what dose.

Peptigrity's independent lab-test database gives an unusually clear view here, because retatrutide is the single most-tested compound on the platform — 624 independent HPLC purity tests at a 99.65% average across 219 shops (verified June 2026), out of more than 9,000 lab tests tracked platform-wide. The encouraging finding is that chemical purity is usually high: most retatrutide samples test at or above 99% by high-performance liquid chromatography (HPLC). The concerning finding is in the quantity. Recent retatrutide tests frequently show vials that contain more peptide than the label states — overages in the range of roughly +4% to +20%, with occasional extreme outliers exceeding +50%. An overfilled vial is not a bonus; it means the actual delivered dose is unknown, which turns careful titration into guesswork and raises the risk of amplified side effects.

That is why purity alone is an incomplete check. A vial can be 99.9% pure retatrutide and still contain 30% more drug than its label claims. Verifying a source means confirming both chemical identity and purity (HPLC plus mass spectrometry) and the actual quantity against the stated label. The practical steps — what a clean certificate of analysis looks like, which red flags to watch for, and how to read the numbers — are laid out in how to verify retatrutide before buying it, and the underlying testing methods are explained in how peptide testing works. If you are modeling doses from a multi-milligram vial, a retatrutide dosing calculator helps translate concentration into draw volume — though it can only ever be as accurate as the vial's true contents.

What's the regulatory status and approval timeline?

As of June 2026, retatrutide is not approved by any drug regulator anywhere in the world — it remains investigational, and its entire evidence base exists to support a future approval application rather than a current one. It has no approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Eli Lilly has signaled a U.S. regulatory submission around late 2026, which means the earliest realistic approval and pharmacy availability would follow after that review.

Because the compound is unapproved, there is no legal prescription pathway and no legitimately compounded version — retatrutide is not in the same regulatory situation as semaglutide or tirzepatide, which are approved drugs that were, at various points, available through compounding pharmacies under specific conditions. Regulatory status in this space moves quickly, so any specific claim should be re-checked against current sources at the time of reading; this article reflects the position as of June 2026. For the broader policy backdrop, see the 2025–2026 FDA peptide-regulation timeline, and for the practical legal question, whether you need a prescription for retatrutide.

Frequently Asked Questions

How many TRIUMPH trials are there?

The TRIUMPH program is built from several large registrational trials — including four core weight-management trials (TRIUMPH-1 through TRIUMPH-4), a cardiovascular-outcomes study of roughly 10,000 patients (TRIUMPH-OUTCOMES), and related Phase 3 work such as the companion diabetes trial TRANSCEND-T2D-1 — enrolling more than 5,800 participants across the core studies. This article lists each trial, its population, and its current status in the roster table above.

Which TRIUMPH trials have finished?

As of June 2026, two core trials have reported topline results: TRIUMPH-1 (pivotal obesity, May 2026) and TRIUMPH-4 (obesity with knee osteoarthritis, December 2025). The type 2 diabetes trial (TRIUMPH-2), the cardiovascular-disease trial (TRIUMPH-3), and the large cardiovascular-outcomes study (TRIUMPH-OUTCOMES) are still ongoing, with further readouts expected through 2026.

Is the TRIUMPH-1 data peer-reviewed?

Not yet. TRIUMPH-1's results were released as a company topline announcement, which summarizes the primary endpoints but is not the same as a full, peer-reviewed journal publication. The complete dataset — including full safety tables and subgroup analyses — is pending publication. By contrast, retatrutide's Phase 2 obesity, diabetes, and liver trials are already peer-reviewed and published.

Is retatrutide better than tirzepatide for weight loss?

Cross-trial numbers favor retatrutide — roughly 28% mean weight loss in TRIUMPH-1 versus about 22.5% for tirzepatide in SURMOUNT-1 — but these come from separate trials with different populations and designs. No head-to-head trial has reported as of June 2026, so retatrutide's apparent edge is a reasonable hypothesis rather than a settled result.

When will retatrutide be FDA approved?

Retatrutide is unapproved as of June 2026. Eli Lilly has signaled a U.S. regulatory submission around late 2026; any approval and subsequent pharmacy availability would follow that review process, so a realistic approval date depends on submission timing and FDA review. There is no approved or legally compounded retatrutide available in the meantime.

Is gray-market retatrutide the same as the trial drug?

No. The TRIUMPH results were achieved with pharmaceutical-grade retatrutide dosed under medical supervision, while consumer vials come from the unregulated research-chemical market. Peptigrity's lab data shows purity is usually high but that vials frequently run over their labeled dose, so any source must be independently verified for both identity/purity and actual quantity before its contents can be trusted.

This article is for educational and harm-reduction purposes only and does not constitute medical advice. Retatrutide is an investigational compound that is not approved for human use by the FDA, EMA, MHRA, or any other regulatory authority as of June 2026; references to clinical-trial results describe research conducted with pharmaceutical-grade compound under medical supervision and do not imply safety or efficacy for unsupervised use of products obtained outside a regulated supply chain. Peptigrity is an independent review platform that does not sell peptides and has no financial relationship with any vendor. Consult a qualified healthcare professional before making any medical or health-related decision.